Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Remdesivir

- PMLiVE

Novavax moves closer toward launch of US phase 3 COVID-19 vaccine trial

Company also completes enrolment in UK-based phase 3 trial

- PMLiVE

Joint COVID-19 trial begins testing drugs from Amgen, UCB and Takeda

Trial will test therapeutic candidates in hospitalised COVID-19 patients

- PMLiVE

Moderna eyes COVID-19 vaccine approval in the US and the EU

Updated analysis demonstrates efficacy of 94.1%

- PMLiVE

AZ, Oxford University face more scrutiny over COVID-19 vaccine data

WHO’s immunisations director says ‘more than a press release’ is needed

- PMLiVE

COVID-19 infections in England drop by 30% amid national lockdown

Observations come from REACT study led by Imperial College London and Ipsos MORI

- PMLiVE

Moderna and UK sign agreement for additional doses of COVID-19 vaccine

The UK has secured another two million doses on top of previously agreed five million doses

- PMLiVE

Russia says its Sputnik V COVID-19 vaccine is 91.4% effective

Preliminary data demonstrates efficacy of 95% after 42 days

EU flag

EU buys 160 million doses of Moderna’s COVID-19 vaccine

Deal follows positive data readout last week

- PMLiVE

WHO director-general says urgent support is needed for COVAX facility

Immediate funding support totalling $4.3bn is required

- PMLiVE

FDA sets 10 December date for Pfizer’s COVID-19 vaccine meeting

Independent experts will discuss EUA submission for mRNA-based vaccine

- PMLiVE

UK could approve Pfizer’s COVID-19 vaccine this week

The Telegraph reported the possible timeframe on Sunday

regeneron headquarters

Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval

Drug approved to treat high-risk patients with mild to moderate COVID-19

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links